Global Dividend Stocks Featuring Three Top Picks

Simply Wall St

Mon, Jul 21, 2025, 4:31 AM 4 min read

As global markets navigate a landscape of solid corporate earnings and fluctuating inflation rates, investors are increasingly focused on the resilience of dividend stocks. In this environment, a good dividend stock often combines stable financial performance with the ability to generate consistent income, making it an attractive option for those seeking to balance growth with income amidst economic uncertainties.

Click here to see the full list of 1523 stocks from our Top Global Dividend Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Simply Wall St Dividend Rating: ★★★★★☆

Overview: Century Properties Group, Inc. is a real estate company operating in the Philippines with a market capitalization of approximately ₱8.58 billion.

Operations: Century Properties Group, Inc. generates revenue from several segments including Real Estate Development at ₱13.15 billion, Leasing at ₱1.12 billion, and Property and Hotel Management at ₱626.82 million.

Dividend Yield: 6.6%

Century Properties Group’s dividend strategy reflects a robust financial position, with a payout ratio of 20.7% covered by earnings and an 84% cash payout ratio. Recent policy enhancements increased the regular dividend from 10% to 20% of net income, alongside a special dividend for 2025, totaling P610.63 million. Despite past volatility in dividends, the company’s strong earnings growth and strategic pivot towards faster turnover projects bolster its ability to sustain these payouts.

• Click here and access our complete dividend analysis report to understand the dynamics of Century Properties Group.

• The valuation report we’ve compiled suggests that Century Properties Group’s current price could be inflated.

Simply Wall St Dividend Rating: ★★★★★☆

Overview: Tibet Rhodiola Pharmaceutical Holding Co. operates in the pharmaceutical industry, focusing on the development and sale of traditional Tibetan medicines, with a market cap of CN¥12.36 billion.

Operations: Tibet Rhodiola Pharmaceutical Holding Co. generates its revenue primarily from the development and sale of traditional Tibetan medicines.